Tildrakizumab (MK-3222), an Anti- IL-23p19 Monoclonal Antibody, Improves Psoriasis in a Phase 2b Randomized Placebo- Controlled Trial.

CONCLUSIONS: Tildrakizumab demonstrated superior efficacy vs. placebo that was maintained up to 52 weeks of treatment and for an additional 20 weeks after cessation of study therapy. Tildrakizumab was generally safe and well tolerated. These results suggest that IL-23p19 is a key target for suppressing psoriasis. ClinicalTrials Registry # NCT01225731 This article is protected by copyright. All rights reserved.
PMID: 26042589 [PubMed - as supplied by publisher]

Source: The British Journal of Dermatology - June 3, 2015 Category: Dermatology Authors: Papp K, Thaçi D, Reich K, Riedl E, Langley RG, Krueger JG, Gottlieb AB, Nakagawa H, Bowman EP, Mehta A, Li Q, Zhou Y, Shames R Tags: Br J Dermatol Source Type: research